Chris Gibson, Recursion CEO (Vaughn Ridley/Sportsfile for Web Summit via Getty Images)
August 29, 2024 10:00 AM EDT
R&D
AI
In Focus

Re­cur­sion nears ‘mo­ment of truth’ with first key da­ta, kick­ing off 18-month flur­ry of read­outs

Andrew Dunn

Senior Biopharma Correspondent

Max Gelman

Senior Editor

Af­ter years of talk­ing up ar­ti­fi­cial in­tel­li­gence’s po­ten­tial to help make drugs, Re­cur­sion will fi­nal­ly bring da­ta to the ta­ble — and lots of it. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

SEC probe of Il­lu­mi­na’s Grail deal tar­gets sales fore­casts, sources say

Post-Hoc: Big promis­es built Mod­er­na. They might al­so be its un­do­ing

FDA ap­proves sub­cu­ta­neous Ocre­vus, broad­en­ing ac­cess to Roche and Genen­tech block­buster

Af­ter a huge IPO and ac­qui­si­tion, Zymer­gen caps off bank­rupt­cy with $30M SEC penal­ty

Doug Williams re­turns with a ‘FIT’ bet on CAR-Ts; Bio­gen ap­points Mene Pan­ga­los to board

Cor­rect­ed: Roche’s Tecen­triq scores first US ap­proval for sub­cu­ta­neous PD-L1

A service from the Financial Times